AbbVie
Trade AbbVie 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About ABBV
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions.
ABBV Key Statistics
Stock Snapshot
With a market cap of 403.35B, AbbVie(ABBV) trades at $228.09. The stock has a price-to-earnings ratio of 96.34 and currently yields dividends of 2.9%.
During the trading session on 2026-03-10, AbbVie(ABBV) shares reached a daily high of $231.27 and a low of $226.53. At a current price of $228.09, the stock is +0.7% higher than the low and still -1.4% under the high.
Trading volume for AbbVie(ABBV) stock has reached 2.86M, versus its average volume of 6.65M.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
Over the past 52 weeks, AbbVie(ABBV) stock has traded between a high of $244.81 and a low of $164.39.
ABBV News
Analyst Geoff Meacham from Citi maintained a Hold rating on AbbVie and keeping the price target at $230.00. Claim 70% Off TipRanks Premium Unlock hedge fund-lev...
Xilio Therapeutics ( (XLO) ) has provided an update. On March 9, 2026, Xilio Therapeutics posted an updated corporate investor presentation outlining its strat...
AbbVie (ABBV) announced positive topline results from the multiple ascending dose part of its Phase 1 study evaluating the safety, tolerability, pharmacokinetic...
Analyst ratings
64%
of 33 ratingsMore ABBV News
Insiders have been trading these 5 stocks: ((XOM)), ((ABBV)), ((CVX)), ((HD)) and ((RIVN)). Here is a breakdown of their recent trades and their value. VP – Co...
AbbVie ABBV reported encouraging fourth-quarter and full-year 2025 results last month. While the company’s immunology portfolio accounted for the bulk of revenu...
AbbVie (NYSE:ABBV) plans to invest US$380 million in two new US active pharmaceutical ingredient manufacturing facilities that will use artificial intelligence...
Image source: The Motley Fool. Thursday, March 5, 2026 at 8 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer — Curran Simpson Chief Medical Offi...
Abbvie (ABBV) announced an update on their ongoing clinical study. AbbVie is running a Phase 2 study in Japan to test venetoclax in adults with relapsed or ref...
Key Points AbbVie had 10 therapies with sales of $1 billion or more each in 2025. The pharma giant has raised its dividends annually for 54 consecutive years....
AbbVie recently reported positive topline Phase 3 results from its AFFIRM trial, showing risankizumab (SKYRIZI) subcutaneous induction led to significantly high...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.